gimli
CIPLA stock analysis context
CIPLA Stock Context for AI Screening
CIPLA LTD is a large-cap stock in Healthcare. This page summarizes key screening signals for CIPLA, including recent returns, momentum indicators, valuation ratios, liquidity, and growth metrics. Gimli uses this context to help users ask natural-language stock screening questions across Indian equities.
Open interactive CIPLA stock pagePrice
₹1,431.80
1W return
-1.71%
1M return
+3.16%
3M return
+17.76%
6M return
-1.97%
1Y return
-3.80%
Market cap
₹115,660.88 cr
PE
29.80
PB
3.35
ROE
+11.79%
ROCE
+10.20%
RSI
54.48
Turnover
₹166.62 cr
Why it can matter in screens
- Momentum: CIPLA is above 50DMA, above 200DMA; RSI is 54.48.
- Returns: 1D -1.38%, 1W -1.71%, 1M +3.16%, 3M +17.76%, 1Y -3.80%.
- Trend levels: 52W high ₹1,663.60, 52W low ₹1,192.40, off high -13.93%.
- Liquidity: latest turnover is ₹166.62 cr; volume vs 20D is +0.69%.
- Valuation/profitability: PE 29.80, PB 3.35, ROE +11.79%, ROCE +10.20%.
- Growth: 3Y sales CAGR +7.23%, 3Y profit CAGR +11.45%.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 6,464.26 cr | 1,103.11 cr | 554.64 cr | 6.87 |
| 2025-12-31 | 6,962.97 cr | 1,185.49 cr | 675.80 cr | 8.37 |
| 2025-09-30 | 7,858.00 cr | 2,164.00 cr | 1,353.00 cr | 16.72 |
| 2025-06-30 | 6,837.04 cr | 2,036.70 cr | 1,297.62 cr | 16.07 |
| 2025-03-31 | 6,597.72 cr | 1,827.05 cr | 1,221.84 cr | 15.13 |
| 2024-12-31 | 6,961.60 cr | 2,210.53 cr | 1,570.51 cr | 19.45 |
| 2024-09-30 | 6,961.22 cr | 2,076.20 cr | n/a | nan |
| 2024-06-30 | 6,624.86 cr | 1,875.99 cr | 1,177.64 cr | 14.58 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 27,711.69 cr | 6,355.48 cr | 3,879.23 cr | 43.49 |
| 2025-03-31 | 27,145.40 cr | 7,860.28 cr | 5,272.52 cr | 65.29 |
| 2024-03-31 | 25,446.63 cr | 6,824.05 cr | 4,121.55 cr | 51.05 |
| 2023-03-31 | 22,473.18 cr | 5,152.10 cr | 2,801.91 cr | 34.72 |
| 2022-03-31 | 16,047.52 cr | 4,588.20 cr | 2,882.58 cr | 31.20 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 42,495.98 cr | 1,018.22 cr | 613.77 cr | 34,520.24 cr |
| 2025-03-31 | 37,387.04 cr | 588.69 cr | 438.19 cr | 31,289.25 cr |
| 2024-03-31 | 32,717.82 cr | 640.07 cr | 559.41 cr | 26,802.33 cr |
| 2023-03-31 | 29,463.28 cr | 627.63 cr | 803.12 cr | 23,713.54 cr |
| 2022-03-31 | 27,101.12 cr | 677.74 cr | 1,055.78 cr | 21,117.38 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 3,940.02 cr | 860.71 cr | n/a |
| 2025-03-31 | 5,004.98 cr | 3,456.78 cr | n/a |
| 2024-03-31 | 4,133.91 cr | 2,784.61 cr | n/a |
| 2023-03-31 | 3,237.65 cr | 2,054.76 cr | n/a |
| 2022-03-31 | 3,325.90 cr | 2,624.75 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-03-31 | +29.21% | +22.56% | +31.97% | +18.66% | +16.25% | +0.00% |
| 2025-12-31 | +29.21% | +23.93% | +30.72% | +19.21% | +16.13% | +0.00% |
| 2025-09-30 | +29.21% | +24.55% | +30.25% | +20.23% | +15.99% | +0.00% |
| 2025-06-30 | +29.19% | +25.25% | +29.26% | +20.44% | +16.30% | +0.00% |
| 2025-03-31 | +29.20% | +26.28% | +28.15% | +20.51% | +16.37% | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 453,042.43 cr | 39.400236 | +14.71% | +12.90% |
| DIVISLAB | DIVI S LABORATORIES LTD | 179,324.04 cr | 69.830233 | +16.19% | -2.64% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 164,701.07 cr | 76.144739 | +17.18% | +46.47% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 125,861.94 cr | 64.267738 | +21.03% | +15.71% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 115,515.66 cr | 23.036787 | +17.93% | +16.76% |
| LUPIN | LUPIN LIMITED | 112,429.39 cr | 21.054508 | +26.83% | +27.93% |
| DRREDDY | DR. REDDY S LABORATORIES | 112,317.04 cr | 26.207396 | +11.94% | +5.08% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 105,577.49 cr | 73.195199 | +14.33% | -16.28% |
Try these prompts
- Analyze CIPLA with valuation, momentum and industry peers
- Compare CIPLA with other Healthcare stocks
- Show large-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View large-cap stocks
- Find stocks above 50DMA
- Compare CIPLA with other Healthcare stocks
Data snapshot: 2026-07-08. Not investment advice.